Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease

J Neurol Sci. 2012 Aug 15;319(1-2):86-8. doi: 10.1016/j.jns.2012.05.010. Epub 2012 May 25.

Abstract

Objectives: Whereas delayed gastric emptying is believed to be a causative factor for producing delayed-on and motor fluctuation in Parkinson's disease (PD), few studies have directly measured levodopa pharmacodynamics and gastric emptying together. In order to determine the relationship, we measured these two parameters in a single PD patients cohort.

Methods: Thirty-one patients with PD were enrolled in the study. They were 11 men and 20 women; age, 68.1 ± 7.8 years; disease duration, 4.2 ± 3.8 years; Unified Parkinson's Disease Rating Scale Part 3 Motor Score 18.37 ± 8.60; bowel movement <3 times a week in 20; all taking 301 mg ± 94 mg/day levodopa/carbidopa. All patients underwent levodopa pharmacokinetic study and the gastric emptying study using (13)C-octanoic acid expiration breath test. Statistical analysis was performed by Student's t-test and Mann-Whitney's U test.

Results: Pharmacokinetic study showed that the plasma levodopa peak was at 2 hours in 42% (13/31 patients) whereas at 1 hour in 58% (18/31 patients), total of 50.7 ± 16.4 min (mean ± standard deviation) in all 31 patients. The gastric emptying study showed that T(max) ((13)C)>60 min was more common in patients with a plasma levodopa peak at 2 hours (14/18, 69%) than in those with a plasma levodopa peak at 1 hour (4/13, 22%) (p<0.05), total of 50.7 ± 16.4 min in all 31 patients.

Conclusion: We found a significant relationship between levodopa pharmacokinetics and gastric emptying in PD patients, suggesting that delayed gastric emptying is a causative factor for producing delayed-on in PD. Therefore, studies of improved gastric emptying in order to ameliorate delayed-on in PD are warranted.

MeSH terms

  • Aged
  • Antiparkinson Agents / pharmacokinetics*
  • Antiparkinson Agents / therapeutic use
  • Breath Tests
  • Female
  • Gastric Emptying / physiology*
  • Gastroparesis / complications
  • Gastroparesis / diagnosis*
  • Gastroparesis / physiopathology
  • Humans
  • Levodopa / pharmacokinetics*
  • Levodopa / therapeutic use
  • Male
  • Middle Aged
  • Parkinson Disease / complications
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology

Substances

  • Antiparkinson Agents
  • Levodopa